Metacrine raises $22M series B

Chronic disease company Metacrine Inc. (San Diego, Calif.) raised $22 million in a series B round led by new investor New Enterprise Associates. Existing investors Arch Venture Partners, Polaris, venBio and Alexandria Venture Investments also participated.

Metacrine's lead candidate is MET409, an oral non-bile acid farnesoid X receptor (FXR; NR1H4) agonist that is slated to enter the clinic in 1H18 in healthy volunteers. The trial is expected to be completed by YE18...